Type of Assessment:
Telomeres and telomerase in mesothelioma: Pathophysiology, biomarkers and emerging therapeutic strategies (Review)
International Journal of Oncology 2025 March [Link] Dimitrios Andreikos, Demetrios A Spandidos, Vasiliki Epameinondas Georgakopoulou Abstract Malignant mesothelioma (MM) is a rare but aggressive cancer linked to asbestos exposure and characterized by advanced‑stage disease at presentation. Despite advances in treatment, prognosis remains abysmal, highlighting the imperative for the development of novel biomarkers and treatment approaches.…
Read MoremiRNA-503 inhibition exerts anticancer effects and reduces tumor growth in mesothelioma
Journal of Experimental & Clinical Cancer Research 2025 February 22 [Link] Miriam Piccioni, Francesco Di Meo, Anna Valentino, Virginia Campani, Maddalena Arigoni, Mirella Tanori, Mariateresa Mancuso, Rossana Cuciniello, Marco Tomasetti, Federica Monaco, Gaia Goteri, Enrico P Spugnini, Raffaele A Calogero, Giuseppe De Rosa, Gianfranco Peluso, Alfonso Baldi, Stefania Crispi Abstract Background: Malignant mesothelioma (MM) is…
Read MoreThe phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes
Journal of Translational Medicine 2025 February 20 [Link] Federica Torricelli, Filomena Spada, Cynthia Bishop, Katrina Todd, Daisuke Nonaka, Nedyalko Petrov, Manuela Terranova Barberio, Alan G Ramsay, Richard Ellis, Alessia Ciarrocchi, Benedetta Apollonio, Andrea Billè Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with limited therapeutic options. To improve patients management and…
Read MoreCD276 as a critical independent biomarker and immune checkpoint inhibitor target in epithelioid mesothelioma-TCGA study
Journal of Thoracic Disease 2025 January 24 [Link] Yuko Aoki, Ken Arimura, Kenzo Hiroshima, Yasuto Sato, Mitsuko Kondo, Etsuko Tagaya Abstract Background: CD276 is an immune checkpoint, and immune checkpoint inhibitors (ICIs) targeting CD276 have been tested against various cancers. However, the precise role of CD276 in mesothelioma subtypes is unknown. This study aimed to…
Read MoreDNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy
Journal of Experimental & Clinical Cancer Research 2025 February 18 [Link] Maria Fortunata Lofiego, Rossella Tufano, Emma Bello, Laura Solmonese, Francesco Marzani, Francesca Piazzini, Fabrizio Celesti, Francesca Pia Caruso, Teresa Maria Rosaria Noviello, Roberta Mortarini, Andrea Anichini, Michele Ceccarelli, Luana Calabrò, Michele Maio, Sandra Coral, Anna Maria Di Giacomo, Alessia Covre Abstract Background: Co-targeting of…
Read MorePotential utility of miRNAs derived from pleural fluid extracellular vesicles to differentiate between benign and malignant pleural effusions
Translational Lung Cancer Research 2025 January 24 [Link] Tian Mun Chee, Caeli J Zahra, Kwun M Fong, Ian A Yang, Rayleen V Bowman Abstract Background: Cytological examination is of suboptimal sensitivity but high specificity for the diagnosis of malignant pleural effusions (MPEs). Pleural fluid extracellular vesicles (PFEVs) are enriched with disease-specific microRNAs (miRNAs) which may…
Read MorePrognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
BMC Cancer 2025 February 14 [Link] Zhang Xinjing, Gong Lei, Li Xinbao, Ji Zhonghe, Yang Zhiran, Gao Chao, Zhang Kai, Yan Lijun, Yan Guojun, Yu Junhui, Zhang Yanbin, An Songlin Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare but aggressive cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was the preferred choice for…
Read MorePrognostic Stratification of Epithelioid Pleural Mesothelioma Based on the Hippo-TEADs Network
Cancers 2025 January 30 [Link] Anello Marcello Poma, Rossella Bruno, Iacopo Petrini, Iosè Di Stefano, Alessandra Celi, Andrea Sbrana, Sabrina Cappelli, Antonio Chella, Franca Melfi, Marco Lucchi, Greta Alì Abstract Background. The Hippo pathway is the most frequently altered signaling in pleural mesothelioma (PM). Epithelioid PM (ePM) is associated with better outcome than non-epithelioid subtypes,…
Read MoreDiagnostic Challenges in the Pathological Approach to Pleural Mesothelioma
Cancers 2025 February 1 [Link] Stefano Lucà, Giovanna Pignata, Alessandro Cioce, Cecilia Salzillo, Rossella De Cecio, Gerardo Ferrara, Carminia Maria Della Corte, Floriana Morgillo, Alfonso Fiorelli, Marco Montella, Renato Franco Abstract Malignant pleural mesothelioma (MPM) still represents a complex diagnostic challenge for pathologists in routine practice. This diagnosis requires a multidisciplinary approach, and pathological evaluation…
Read MoreA Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials
Cancers 2025 February 3 [Link] Andrea Messori, Sabrina Trippoli, Eugenia Piragine, Sara Veneziano, Vincenzo Calderone Abstract Background: In unresectable pleural mesothelioma, pemetrexed+cisplatin as first line is considered the standard of care, but novel treatments have been recently proposed. Methods: Our objective was to compare, albeit indirectly, the results of randomized controlled trials on overall survival…
Read More